Olmutinib NEW
| Price | $33 | $52 | $81 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Olmutinib | CAS No.: 1353550-13-6 |
| Purity: 99.27% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Olmutinib |
| Description | Olmutinib (HM61713, BI 1482694) is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild-type form. |
| In vitro | HM61713 causes potent inhibition in cell lines H1975 (L858R and T790M) and HCC827 (exon 19 deletion). It has a low potency for NSCLC cell line H358 harboring wild-type EGFR (GI50 of 2225 nM)[1]. |
| In vivo | HM61713 has a half-life of over 24 h for EGFR inhibition. In the in vivo studies of xenograft models with grafts of H1975 and HCC827, HM61713 is active against the tumors without showing any side effects[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 22 mg/mL (45.2 mM) DMSO : 90 mg/mL (185 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | 1802181-20-9 | Olmutinib | HM-61713 | ErbB-1 | BI1482694 | inhibit | HM61713, BI1482694 | BI-1482694 | HER1 | EGFR | HM61713, BI-1482694 | Epidermal growth factor receptor | Inhibitor | HM 61713 |
| Inhibitors Related | Osimertinib | Lidocaine Hydrochloride hydrate | Lapatinib | Afatinib Dimaleate | Erlotinib hydrochloride | Erlotinib | Neratinib | Chalcone | Genistein | Gefitinib |
| Related Compound Libraries | Apoptosis Compound Library | Cysteine Covalent Library | Cytokine Inhibitor Library | Approved Drug Library | Drug-induced Liver Injury (DILI) Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Prostate Cancer Compound Library | Orally Active Compound Library | Covalent Inhibitor Library | Anti-Liver Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $75.00/1kg |
Anhui Ruihan Technology Co., Ltd
|
2023-08-18 | ||
| $0.00/25KG |
Shandong Huisheng Import & Export Co., Ltd.
|
2023-08-12 | ||
| $0.00/100g |
Anhui Zhongda Biotechnology Co., Ltd
|
2023-08-10 | ||
| $0.00/1gram |
VIP4Y
|
Zhejiang J&C Biological Technology Co.,Limited
|
2022-02-17 | |
| $1.00/1g |
VIP6Y
|
Career Henan Chemical Co
|
2020-02-01 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY